亚胺培南/雷利巴坦对2015年SMART监测项目中17个欧洲国家分离的革兰阴性ESKAPE病原体的体外活性
该研究采用CLSI肉汤微量稀释法测定亚胺培南/雷利巴坦对2015年SMART监测项目中17个欧洲国家临床实验室提交的革兰阴性ESKAPE病原体的体外活性,并按EUCAST折点判读。结果显示,雷利巴坦可恢复部分亚胺培南不敏感菌株对亚胺培南的敏感性,但对鲍曼不动杆菌无此作用。作者认为亚胺培南/雷利巴坦似乎是治疗耐药革兰阴性杆菌感染的有前景的选择。
要点
- 亚胺培南/雷利巴坦对铜绿假单胞菌、肺炎克雷伯菌和肠杆菌属的敏感率分别为94.7%、94.8%和96.8%。
- 雷利巴坦使81.1%的亚胺培南不敏感铜绿假单胞菌和54.2%的亚胺培南不敏感肺炎克雷伯菌恢复对亚胺培南敏感。
- 雷利巴坦未增加鲍曼不动杆菌对亚胺培南敏感的菌株数。
核心结论
- 雷利巴坦使大多数测试的亚胺培南不敏感铜绿假单胞菌和肺炎克雷伯菌以及部分亚胺培南不敏感肠杆菌属分离株恢复对亚胺培南敏感。
- 基于本研究结果,亚胺培南/雷利巴坦似乎是治疗抗菌药物耐药革兰阴性杆菌所致感染的有前景的治疗选择。
研究设计与样本
- 研究为2015年SMART全球监测项目的一部分,评估亚胺培南/雷利巴坦对17个欧洲国家临床实验室提交的革兰阴性ESKAPE病原体的体外活性。
- 采用CLSI标准肉汤微量稀释法测定MIC,按EUCAST临床折点判读。
- 雷利巴坦以固定浓度4 mg/L与倍比稀释的亚胺培南联合测试,亚胺培南/雷利巴坦MIC按亚胺培南折点判读。
主要发现
- 铜绿假单胞菌(n=1705)、肺炎克雷伯菌(n=1591)和肠杆菌属(n=772)对亚胺培南/亚胺培南/雷利巴坦的敏感率分别为72.0%/94.7%、88.7%/94.8%和95.6%/96.8%。
- 雷利巴坦使亚胺培南不敏感铜绿假单胞菌(n=477)、肺炎克雷伯菌(n=179)和肠杆菌属(n=34)中分别81.1%、54.2%和26.5%的分离株恢复对亚胺培南敏感。
- 多数亚胺培南/雷利巴坦不敏感分离株携带MBLs、OXA-48或GES碳青霉烯酶。
- 雷利巴坦未增加鲍曼不动杆菌(n=486)中对亚胺培南敏感的分离株数。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Relebactam is an inhibitor of class A β-lactamases, including KPC β-lactamases, and class C β-lactamases, and is currently under clinical development in combination with imipenem. The objective of the current study was to evaluate the in vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens (Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp.) submitted by clinical laboratories in 17 European countries to the Study for Monitoring Antimicrobial Resistance Trends (SMART) global surveillance programme in 2015. METHODS: MICs were determined using the CLSI standard broth microdilution method and interpreted using EUCAST clinical breakpoints. Relebactam was tested at a fixed concentration of 4 mg/L in combination with doubling dilutions of imipenem. Imipenem/relebactam MICs were interpreted using breakpoints for imipenem. RESULTS: Rates of susceptibility to imipenem and imipenem/relebactam for isolates of P. aeruginosa (n = 1705), K. pneumoniae (n = 1591) and Enterobacter spp. (n = 772) were 72.0/94.7%, 88.7/94.8% and 95.6/96.8%, respectively. Relebactam restored imipenem susceptibility to 81.1%, 54.2% and 26.5% of imipenem-non-susceptible isolates of P. aeruginosa (n = 477), K. pneumoniae (n = 179) and Enterobacter spp. (n = 34). Most imipenem/relebactam-non-susceptible isolates carried MBLs, OXA-48 or GES carbapenemases. Relebactam did not increase the number of isolates of A. baumannii (n = 486) susceptible to imipenem. CONCLUSIONS: Relebactam restored susceptibility to imipenem for the majority of imipenem-non-susceptible isolates of P. aeruginosa and K. pneumoniae tested as well as some isolates of imipenem-non-susceptible Enterobacter spp. Based on our results, imipenem/relebactam appears to be a promising therapeutic option for treating patients with infections caused by antimicrobial-resistant Gram-negative bacilli.
引用
- Karlowsky JA, Lob SH, Kazmierczak KM, et al. In vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme. J Antimicrob Chemother. 2018. PMID: 29659861. doi:10.1093/jac/dky107
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。